Adcendo
Latest round
- Series C
Last raised
- Apr 2026
Total raised
- $324M
Investors
- 18
About Adcendo
Adcendo ApS, located in Frederiksberg, Denmark, is a biotechnology firm focused on developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies, aiming to enhance treatment efficacy and minimize side effects for patients. Founded in 2017 in Frederiksberg, Denmark, Adcendo ApS specializes in developing antibody-drug conjugates (ADCs) to target specific cancer therapies. The company was co-founded by Henrik Stage, Lars Engelholm, and Niels Behrendt, while Michael Pehl serves as the CEO. Adcendo ApS specializes in the development of innovative antibody-drug conjugates (ADCs), which deliver targeted cancer therapies. Their primary product, ADCE-D01, targets uPARAP, an endocytic receptor overexpressed in mesenchymal cancers, particularly various subtypes of soft tissue sarcoma. This approach aims to improve treatment specificity and efficacy, focusing primarily on patients with high unmet medical needs in the clinical market, especially in the United States and Europe. Adcendo's revenue model is based on partnerships and collaborations with biotech firms and potential licensing agreements for their ADC technologies.
Who invested in Adcendo
18 investors across 5 rounds
See all investors in Adcendo
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adcendo
Who invested in Adcendo?
Adcendo has 18 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adcendo raised?
Adcendo has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Adcendo last raise money?
Adcendo's most recent round on record is a Series C, in Apr 2026.
What does Adcendo do?
Adcendo ApS, located in Frederiksberg, Denmark, is a biotechnology firm focused on developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies, aiming to enhance treatment efficacy and minimize side effects for patients.
Where is Adcendo headquartered?
Adcendo is headquartered in Frederiksberg, Denmark.
Which VCs invest in companies like Adcendo?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Adcendo's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Adcendo? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.